1.Black Raspberry Improved Lipid Profiles and Vascular Endothelial Function in Patients with Metabolic Syndrome: A Subgroup Analysis of Statin Naïve Participants.
Hee Jun MYUNG ; Han Saem JEONG ; Tae Yeon HWANG ; Kyoung Ho GO ; Juwon KIM ; Woori CHO ; Yoon Kyung CHOI ; Jiae PARK ; Soon Jun HONG
Journal of Lipid and Atherosclerosis 2016;5(1):49-59
OBJECTIVE: Black raspberry (Rubus occidentalis) has been known for its anti-inflammatory and anti-oxidant effects and for improving vascular endothelial function in patients at high-risk for cardiovascular disease. We investigated short-term effects of black raspberry on lipid profiles, vascular endothelial function and circulating endothelial progenitor cells in statin naïve participants with metabolic syndrome. METHODS: Patients with metabolic syndrome (n=51) without lipid lowering medications were prospectively randomized into the black raspberry group (n=26, 750 mg/day) and placebo group (n=25) during the 12-week follow-up. Lipid profiles, brachial artery flow-mediated dilatation (baFMD) and inflammatory cytokines such as IL-6, TNF-α, C-reactive protein, adiponectin, sICAM-1, sVCAM-1 were measured at baseline and at 12-week follow-up. Central blood pressure and augmentation index were also measured at baseline and at 12-week follow-up. RESULTS: Decreases from baseline in total cholesterol levels (-22.7±34.3 mg/dL vs. 0.0±34.7mg/dL, p<0.05, respectively) and total cholesterol/HDL ratio (-0.34±0.68 vs. 0.17±0.56, p<0.05, respectively) were significantly greater in the black raspberry group when compared to the placebo group. Decreases from baseline in IL-6 (-0.5±1.4 pg/mL vs. -0.1±1.1 pg/mL, p<0.05, respectively) and TNF-α levels (-5.4±4.5 pg/mL vs. -0.8±4.0 pg/mL, p<0.05, respectively) were significantly greater in the black raspberry group. Increases from the baseline in adiponectin levels (2.9±2.1 µg/mL vs. -0.2±2.5 µg/mL, p<.05) were significant in the black raspberry group. Increases in baFMD at 12-week follow-up were significantly greater in the black raspberry group when compared to the placebo group (2.9±3.6 mm vs. 1.0±3.9 mm, p<0.05, respectively). Radial augmentation indexes were significantly decreased in the black raspberry group when compared to the placebo group (-2±10% vs. 4±13%, p<0.05). CONCLUSION: The use of black raspberry significantly decreased serum total cholesterol levels, inflammatory cytokines, and augmentation index, thereby improving vascular endothelial function in statin naïve participants with metabolic syndrome during the 12-week follow-up.
Adiponectin
;
Antioxidants
;
Blood Pressure
;
Brachial Artery
;
C-Reactive Protein
;
Cardiovascular Diseases
;
Cholesterol
;
Cytokines
;
Dilatation
;
Endothelial Progenitor Cells
;
Follow-Up Studies
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
;
Interleukin-6
;
Prospective Studies
;
Rubus*
2.Single Fulcrum Laparoscopic Cholecystectomy in Situs Inversus Totalis.
Sun Jung KIM ; Jiae PARK ; Chang Moo KANG ; Woo Jung LEE
Journal of Minimally Invasive Surgery 2015;18(3):89-92
Single fulcrum laparoscopic cholecystectomy (SFLC) is a modified version of single incision laparoscopic cholecystectomy (SILC). In this article we report on the first experience of SFLC in a patient with situs inversus totalis (SIT). A 36-year-old female patient with SIT whose gallbladder was located on the left side was admitted to hospital due to a symptomatic gallbladder stone; 2 cm of transumbilical skin and subcutaneous fat layer were dissected and the fascia layer was left undissected to make two openings at the upper and lower part each, dividing where trocars were placed. Compared to conventional SFLC or SILC, the right hand, which is dominant for most people, performed the main operating movements, such as cutting and clipping, while the other hand was retracting the fundus of the gallbladder to show the Calot triangle. SFLC is a facilitating operation in that it does not require a specialized trocar or instruments, and is also convenient for a patient with SIT.
Adult
;
Cholecystectomy, Laparoscopic*
;
Fascia
;
Female
;
Gallbladder
;
Hand
;
Humans
;
Situs Inversus*
;
Skin
;
Subcutaneous Fat
;
Surgical Instruments
3.Improvement of andropause symptoms by dandelion and rooibos extract complex CRS-10 in aging male.
Yoo Hun NOH ; Do Hee KIM ; Joon Yub KIM ; Jiae PARK ; Ok Hyeon KIM ; Daeseok HAN ; Won Yong KIM ; Sung Su KIM ; Moo Yeol LEE ; Seok Hyun HEO ; Misook KIM ; Won Bok LEE ; Yoonhwa JEONG ; Soon Chul MYUNG
Nutrition Research and Practice 2012;6(6):505-512
Many aging male suffer various andropause symptoms including loss of physical and mental activities. This study evaluated the putative alleviative effects of CRS-10 dandelion and rooibos extract complex (CRS-10) on the symptoms of andropause. The survival rate of TM3 Leydig cells (TM3 cells) treated with CRS-10 was measured based on typical physiological stress. After daily intake of CRS-10 for 4 weeks, the level of testosterone, physical activity and both the number and activity of sperm in older rats (18 weeks) were measured. Furthermore, thirty males were surveyed with AMS (Aging Males' Symptoms) questionnaire after intake of 400 mg of CRS-10. Overall, CRS-10 protected TM3 cells from serum restriction and oxidative stress via activation of ERK and Akt pathways. The level of testosterone and activation of spermatogenesis in rats were significantly enhanced. In addition, physical locomotion was markedly improved. Daily intake of 400 mg of CRS-10 improved the quality of life among agingmale respondents, according to a clinical survey using the AMS. The results indicate the potential of CRS-10 as a safe and efficacious natural substance for reducing or alleviating andropause symptoms.
Aging
;
Andropause
;
Animals
;
Aspalathus
;
Humans
;
Leydig Cells
;
Locomotion
;
Male
;
Motor Activity
;
Oxidative Stress
;
Quality of Life
;
Surveys and Questionnaires
;
Rats
;
Spermatogenesis
;
Spermatozoa
;
Stress, Physiological
;
Survival Rate
;
Taraxacum
;
Testosterone
4.Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
Kyung Hwan KIM ; Joon Young HUR ; Jiae KOH ; Jinhyun CHO ; Bo Mi KU ; June Young KOH ; Jong-Mu SUN ; Se-Hoon LEE ; Jin Seok AHN ; Keunchil PARK ; Myung-Ju AHN ; Eui-Cheol SHIN
Immune Network 2020;20(6):e48-
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in patients with HPD. We prospectively recruited patients with metastatic non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs between April 2015 and April 2018, and collected peripheral blood before treatment and 7-days post-treatment. HPD was defined as ≥2-fold increase in both tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment.Peripheral blood mononuclear cells were analyzed by multi-color flow cytometry to phenotype the immune cells. Of 115 patients, 19 (16.5%) developed HPD, 52 experienced durable clinical benefit (DCB; partial response or stable disease ≥6 months), and 44 experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly lower progression-free survival (p<0.001) and overall survival (p<0.001). When peripheral blood immune cells were examined, the pre-treatment frequency of CD39+ cells among CD8+T cells was significantly higher in patients with HPD compared to those with NHPD, although it showed borderline significance to predict HPD. Other parameters regarding regulatory T cells or myeloid derived suppressor cells did not significantly differ among patient groups. Our findings suggest high pre-treatment frequency of CD39+ CD8+ T cells might be a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our results and better delineate the immune landscape of HPD.
5.Benzydamine inhibits osteoclast differentiation and bone resorption down-regulation of interleukin-1 expression.
Han Saem SON ; Jiae LEE ; Hye In LEE ; Narae KIM ; You-Jin JO ; Gong-Rak LEE ; Seong-Eun HONG ; Minjeong KWON ; Nam Young KIM ; Hyun Jin KIM ; Jin Ha PARK ; Soo Young LEE ; Woojin JEONG
Acta Pharmaceutica Sinica B 2020;10(3):462-474
Bone diseases such as osteoporosis and periodontitis are induced by excessive osteoclastic activity, which is closely associated with inflammation. Benzydamine (BA) has been used as a cytokine-suppressive or non-steroidal anti-inflammatory drug that inhibits the production of pro-inflammatory cytokines or prostaglandins. However, its role in osteoclast differentiation and function remains unknown. Here, we explored the role of BA in regulating osteoclast differentiation and elucidated the underlying mechanism. BA inhibited osteoclast differentiation and strongly suppressed interleukin-1 (IL-1) production. BA inhibited osteoclast formation and bone resorption when added to bone marrow-derived macrophages and differentiated osteoclasts, and the inhibitory effect was reversed by IL-1 treatment. The reporter assay and the inhibitor study of IL-1 transcription suggested that BA inhibited nuclear factor-B and activator protein-1 by regulating IB kinase, extracellular signal regulated kinase and P38, resulting in the down-regulation of IL-1 expression. BA also promoted osteoblast differentiation. Furthermore, BA protected lipopolysaccharide- and ovariectomy-induced bone loss in mice, suggesting therapeutic potential against inflammation-induced bone diseases and postmenopausal osteoporosis.